Wrapping up presentations at this years annual Liver Meetings in Boston, Dr. Eric Lawitz presented data on 2 new antiviral agents to treat chronic hepatitis C. This study looked at the more tough to treat populations.
These two drugs use in cirrhotic patients and those prior null responder to Peg-intron and ribavirin had between a 91-100% SVR.
The full article is posted in this weeks Lancet Journal.
Throughout the meeting, very encouraging data was presented about the very high cure rates we are seeing in hepatitis C. With no less than 6 new drugs being developed, in the months ahead, we will all see the slow evolution of these therapies, selecting specific drug combinations tailored to unique patient features, such as HCV genotype, prior response to therapy, presence or absence of cirrhosis, renal failure (with or without dialysis), HIV status, and whether the patient has had a liver transplant.
As with all of these therapies, cost will be factored into the course of treatment.